Clarification of Hot Issues of Immune-Related Adverse Events
10.3971/j.issn.1000-8578.2024.24.0522
- VernacularTitle:免疫相关不良事件热点问题解析
- Author:
Yang FU
1
;
Jun WANG
2
;
Bicheng ZHANG
3
Author Information
1. Department of Oncology and Hematology, Xiangyang Hospital, Hubei University of Chinese Medicine, Xiangyang 441001, China.
2. Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, China.
3. Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China.
- Publication Type:SPECIALFEATURE
- Keywords:
Immune checkpoint inhibitors;
Immune-related adverse events;
Clarification
- From:
Cancer Research on Prevention and Treatment
2024;51(9):718-726
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy, represented by immune checkpoint inhibitors, may lead to immune-related adverse events (irAEs) while demonstrating favorable efficacy in patients with malignant tumors. Many domestic and international guidelines or consensus have been established to assist clinicians in effectively managing the majority of irAEs. However, further exploration about irAEs is required regarding the definition and determination, temporal patterns, individual variances, utilization of hormones and immunosuppressants, correlation between irAEs and therapeutic outcomes, immune reactivation, and special populations. The identification and management of severe, refractory, and multiple irAEs necessitate additional solutions. This paper aims to clarify 10 prominent issues concerning irAEs individually and provide assistance for clinicians.
